Øystein Sandanger

2.2k total citations · 1 hit paper
31 papers, 1.5k citations indexed

About

Øystein Sandanger is a scholar working on Immunology, Molecular Biology and Epidemiology. According to data from OpenAlex, Øystein Sandanger has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Immunology, 11 papers in Molecular Biology and 6 papers in Epidemiology. Recurrent topics in Øystein Sandanger's work include Inflammasome and immune disorders (10 papers), Immune Response and Inflammation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Øystein Sandanger is often cited by papers focused on Inflammasome and immune disorders (10 papers), Immune Response and Inflammation (7 papers) and Chronic Lymphocytic Leukemia Research (5 papers). Øystein Sandanger collaborates with scholars based in Norway, United States and Germany. Øystein Sandanger's co-authors include Terje Espevik, Arne Yndestad, Pål Aukrust, Trine Ranheim, Harald Husebye, Leif Erik Vinge, Øyvind Halaas, Andreas Brech, Eicke Latz and Bjarne Bogen and has published in prestigious journals such as SHILAP Revista de lepidopterología, The EMBO Journal and The Journal of Immunology.

In The Last Decade

Øystein Sandanger

31 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia–reperfusion injury

2013 435 citations Øystein Sandanger, Trine Ranheim et al. profile →

Peers

Countries citing papers authored by Øystein Sandanger

Since Specialization

Citations

This map shows the geographic impact of Øystein Sandanger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Øystein Sandanger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Øystein Sandanger more than expected).

Fields of papers citing papers by Øystein Sandanger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Øystein Sandanger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Øystein Sandanger. The network helps show where Øystein Sandanger may publish in the future.

Co-authorship network of co-authors of Øystein Sandanger

This figure shows the co-authorship network connecting the top 25 collaborators of Øystein Sandanger. A scholar is included among the top collaborators of Øystein Sandanger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Øystein Sandanger. Øystein Sandanger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Apigenin inhibits NLRP3 inflammasome activation in monocytes and macrophages independently of CD38 2025 ·Frontiers in Immunology ·Knut H. Lauritzen, Kuan Yang, Michael Frisk, Mieke C. Louwe, Maria Belland Olsen, Mathias Ziegler, William E. Louch, Bente Halvorsen, Pål Aukrust, Arne Yndestad, Øystein Sandanger	2
2	CD38 deficient mice are not protected from atherosclerosis 2024 ·Biochemical and Biophysical Research Communications ·Xiang Yi Kong, Knut H. Lauritzen, Tuva B. Dahl, Sverre Holm, Maria Belland Olsen, Mona Skjelland, Christopher Sivert Nielsen, Annika E. Michelsen, Thor Ueland, Pål Aukrust, Bente Halvorsen, Øystein Sandanger	1
3	Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials 2024 ·The Lancet Rheumatology ·(unknown), Johanna Elin Gehin, (unknown), David J. Warren, Rolf Anton Klaasen, Joseph Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Jørgen Jahnsen, Nils Bolstad, Kristin Kaasen Jørgensen, Espen A. Haavardsholm, Guro Løvik Goll, Silje Watterdal Syversen	7
4	HLA‐DQ2 is associated with anti‐drug antibody formation to infliximab in patients with immune‐mediated inflammatory diseases 2023 ·Journal of Internal Medicine ·(unknown), (unknown), Marte K. Viken, Grethe‐Elisabeth Stenvik, Rolf Anton Klaasen, Johanna Elin Gehin, David J. Warren, Joseph Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Espen A. Haavardsholm, Jørgen Jahnsen, Guro Løvik Goll, Benedicte A. Lie, Nils Bolstad, Kristin Kaasen Jørgensen, Silje Watterdal Syversen	7
5	Nonintensive topical gentamicin treatment of patients with severe epidermolysis bullosa caused by nonsense mutations 2023 ·SHILAP Revista de lepidopterología ·Øystein Sandanger, (unknown), (unknown), (unknown), Jan Cezary Sitek	2
6	OP0060 CLINICAL CONSEQUENCES OF INFLIXIMAB IMMUNOGENICITY AND THE IMPACT OF THERAPEUTIC DRUG MONITORING: SECONDARY ANALYSES OF A RANDOMISED CLINICAL TRIAL 2023 ·Annals of the Rheumatic Diseases ·(unknown), (unknown), Johanna Elin Gehin, (unknown), Rolf Anton Klaasen, Joe Sexton, Øystein Sandanger, Tore K Kvien, Cato Mørk, Jørgen Jahnsen, Nils Bolstad, (unknown), Espen A. Haavardsholm, Guro Løvik Goll, (unknown)	3
7	Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial 2022 ·Journal of Internal Medicine ·(unknown), Guro Løvik Goll, Kristin Kaasen Jørgensen, Joseph Sexton, Johanna Elin Gehin, Øystein Sandanger, Inge Christoffer Olsen, Rolf Anton Klaasen, David J. Warren, Cato Mørk, Tore K Kvien, Jørgen Jahnsen, Nils Bolstad, Espen A. Haavardsholm, Silje Watterdal Syversen	26
8	OP09 Proactive Therapeutic Drug Monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study 2022 ·Journal of Crohn s and Colitis ·(unknown), (unknown), Guro Løvik Goll, (unknown), Øystein Sandanger, Joe Sexton, (unknown), Geir Noraberg, Carl Magnus Ystrøm, Kathrine Aglen Seeberg, Ingrid Marianne Blomgren, Roald Torp, Cato Mørk, Tore K Kvien, Nils Bolstad, Espen A. Haavardsholm, Jørgen Jahnsen	1
9	231: PROACTIVE THERAPEUTIC DRUG MONITORING IS SUPERIOR TO STANDARD TREATMENT DURING MAINTENANCE THERAPY WITH INFLIXIMAB; RESULTS FROM A 52-WEEK MULTICENTRE RANDOMISED TRIAL OF 450 PATIENTS 2022 ·Gastroenterology ·(unknown), Silje Watterdal Syversen, Guro Løvik Goll, (unknown), Øystein Sandanger, Joe Sexton, (unknown), (unknown), Tore K Kvien, Johanna Elin Gehin, Inge Christoffer Olsen, Nils Bolstad, Espen A. Haavardsholm, Jørgen Jahnsen	1
10	Targeting the Inflammasome in Cardiovascular Disease 2021 ·JACC Basic to Translational Science ·Maria Belland Olsen, Ida Gregersen, Øystein Sandanger, Kuan Yang, Marina Sokolova, (unknown), Lars Gullestad, Kaspar Broch, Pål Aukrust, Mieke C. Louwe	105
11	Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study) 2020 ·Trials ·Silje Watterdal Syversen, Guro Løvik Goll, Kristin Kaasen Jørgensen, Inge Christoffer Olsen, Øystein Sandanger, Johanna Elin Gehin, David J. Warren, Joseph Sexton, Cato Mørk, Jørgen Jahnsen, Tore K Kvien, Nils Bolstad, Espen A. Haavardsholm	27
12	Mammalian Target of Rapamycin (mTOR) and the Proteasome Attenuates IL-1β Expression in Primary Mouse Cardiac Fibroblasts 2019 ·Frontiers in Immunology ·(unknown), Kuan Yang, Trine Ranheim, Knut H. Lauritzen, Katrine Alfsnes, Leif Erik Vinge, Pål Aukrust, Kåre‐Olav Stensløkken, Arne Yndestad, Øystein Sandanger	13
13	Interleukin 27 is increased in carotid atherosclerosis and promotes NLRP3 inflammasome activation 2017 ·PLoS ONE ·Ida Gregersen, Øystein Sandanger, Erik T. Askevold, Ellen Lund Sagen, Kuan Yang, Sverre Holm, Turid M. Pedersen, Mona Skjelland, Kirsten Krohg‐Sørensen, Trond Vidar Hansen, Tuva B. Dahl, Kari Otterdal, Terje Espevik, Pål Aukrust, Arne Yndestad, Bente Halvorsen	23
14	Palmitate promotes inflammatory responses and cellular senescence in cardiac fibroblasts 2016 ·Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids ·Marina Sokolova, Leif Erik Vinge, Katrine Alfsnes, Maria Belland Olsen, Lars Eide, (unknown), Håvard Attramadal, (unknown), (unknown), Azita Rashidi, Egil Lien, Alexandra Vanessa Finsen, Øystein Sandanger, Pål Aukrust, Trine Ranheim, Arne Yndestad	44
15	Low Circulating Levels of Mitochondrial and High Levels of Nuclear DNA Predict Mortality in Chronic Heart Failure 2016 ·Journal of Cardiac Failure ·(unknown), Thor Ueland, Christen P. Dahl, Erik T. Askevold, Øystein Sandanger, Arnt E. Fiane, Ingrid Kristine Ohm, Ivar Sjaastad, Alexandra Vanessa Finsen, Anne Wæhre, Lars Gullestad, Pål Aukrust, Arne Yndestad, Leif Erik Vinge	21
16	Sustained Toll-Like Receptor 9 Activation Promotes Systemic and Cardiac Inflammation, and Aggravates Diastolic Heart Failure in SERCA2a KO Mice 2015 ·PLoS ONE ·(unknown), Ivar Sjaastad, Helge Scott, Øystein Sandanger, Lili Zhang, (unknown), Jan Magnus Aronsen, Trine Ranheim, Sigve Holmen, Katrine Alfsnes, (unknown), Håvard Attramadal, Lars Gullestad, Pål Aukrust, Geir Christensen, Arne Yndestad, Leif Erik Vinge	11
17	NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective 2015 ·Biochemical and Biophysical Research Communications ·Øystein Sandanger, Erhe Gao, Trine Ranheim, Marte Bliksøen, (unknown), Kristian Alfsnes, Ståle H. Nymo, Azita Rashidi, Ingrid Kristine Ohm, Håvard Attramadal, Pål Aukrust, Leif Erik Vinge, Arne Yndestad	88
18	Toll-Like Receptor 9 Mediated Responses in Cardiac Fibroblasts 2014 ·PLoS ONE ·Ingrid Kristine Ohm, Katrine Alfsnes, Maria Belland Olsen, Trine Ranheim, Øystein Sandanger, Tuva B. Dahl, Pål Aukrust, Alexandra Vanessa Finsen, Arne Yndestad, Leif Erik Vinge	15
19	Cellular sources and inducers of cytokines present in acute wound fluid 2011 ·Wound Repair and Regeneration ·Øystein Grimstad, Øystein Sandanger, Liv Ryan, Kari Otterdal, (unknown), Brita Pukstad, Terje Espevik	51
20	Endocytic pathways regulate Toll‐like receptor 4 signaling and link innate and adaptive immunity 2006 ·The EMBO Journal ·Harald Husebye, Øyvind Halaas, Harald Stenmark, Gro Tunheim, Øystein Sandanger, Bjarne Bogen, Andreas Brech, Eicke Latz, Terje Espevik	379

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact